Multi-omics Mendelian randomization integrated with single-cell sequencing prioritizes HEBP1 as a candidate mechanistic target for ischemic stroke

Globally, stroke remains the second-leading cause of death and the third-leading contributor to disability, posing a persistent challenge in medical research. We employed an integrative multi-omics approach combining DNA methylation, gene expression, and protein abundance data. Summary-data-based Mendelian randomization (SMR) with HEIDI testing was used to prioritize molecular traits sharing a causal variant with ischemic stroke (IS). Complementary two-sample Mendelian randomization analyses using the inverse-variance weighted (IVW) method, together with colocalization analysis, were also performed. These analyses were supplemented by animal experiments and single-cell sequencing to systematically explore IS-associated genes and therapeutic targets. The integrative analysis prioritized heme-binding protein 1 (HEBP1) as a candidate risk-associated factor. Western blot and qPCR confirmed elevated HEBP1 expression in middle cerebral artery occlusion (MCAO) rat models. Single-cell analysis localized relatively high HEBP1 expression to oligodendrocytes and showed variation along the inferred differentiation trajectory. Immune-metabolic analysis highlighted HEBP1’s role in rejection, complement activation, and cholesterol homeostasis. The Comparative Toxicogenomics Database (CTD) identified 17 chemicals with curated HEBP1 associations, and exploratory docking yielded a predicted score of −5.55 kcal/mol for phenobarbital. Because this modest in silico score and the CTD annotations do not establish direct binding or inhibition, the chemical findings were considered hypothesis-generating. This study prioritizes HEBP1 as a candidate mechanistic mediator of ischemic stroke through convergent multi-omics, single-cell, and animal-model evidence. Cell-specific perturbation, brain-relevant molecular validation, and direct target-engagement studies are required to determine causal direction, safety, and therapeutic tractability before clinical application can be considered.

Authors

Institutions

Publication Details

Journal
BMC Medical Genomics
Published
2026-11-19
DOI
https://doi.org/10.1186/s12920-026-02504-5
Primary Topic
Genetic Associations and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multi-omics Mendelian randomization integrated with single-cell sequencing prioritizes HEBP1 as a candidate mechanistic target for ischemic stroke

Xinxin Zhang, Xin Wang, Qiao Zhang, Rong Liu et al.
BMC Medical Genomics
Genetic Associations and Epidemiology
article

Multi-omics Mendelian randomization integrated with single-cell sequencing prioritizes HEBP1 as a candidate mechanistic target for ischemic stroke

Xinxin Zhang, Xin Wang, Qiao Zhang, Rong Liu, Yalong Qiu, Jinhan He
article en

Abstract

Globally, stroke remains the second-leading cause of death and the third-leading contributor to disability, posing a persistent challenge in medical research. We employed an integrative multi-omics approach combining DNA methylation, gene expression, and protein abundance data. Summary-data-based Mendelian randomization (SMR) with HEIDI testing was used to prioritize molecular traits sharing a causal variant with ischemic stroke (IS). Complementary two-sample Mendelian randomization analyses using the inverse-variance weighted (IVW) method, together with colocalization analysis, were also performed. These analyses were supplemented by animal experiments and single-cell sequencing to systematically explore IS-associated genes and therapeutic targets. The integrative analysis prioritized heme-binding protein 1 (HEBP1) as a candidate risk-associated factor. Western blot and qPCR confirmed elevated HEBP1 expression in middle cerebral artery occlusion (MCAO) rat models. Single-cell analysis localized relatively high HEBP1 expression to oligodendrocytes and showed variation along the inferred differentiation trajectory. Immune-metabolic analysis highlighted HEBP1’s role in rejection, complement activation, and cholesterol homeostasis. The Comparative Toxicogenomics Database (CTD) identified 17 chemicals with curated HEBP1 associations, and exploratory docking yielded a predicted score of −5.55 kcal/mol for phenobarbital. Because this modest in silico score and the CTD annotations do not establish direct binding or inhibition, the chemical findings were considered hypothesis-generating. This study prioritizes HEBP1 as a candidate mechanistic mediator of ischemic stroke through convergent multi-omics, single-cell, and animal-model evidence. Cell-specific perturbation, brain-relevant molecular validation, and direct target-engagement studies are required to determine causal direction, safety, and therapeutic tractability before clinical application can be considered.

BMC Medical Genomics
Guangzhou University of Chinese Medicine (CN)
Genetic Associations and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon